Jump to content

Roledumab

Add links
From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Entranced98 (talk | contribs) at 12:39, 13 May 2023 (Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound"). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Roledumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetRHD
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Roledumab is a monoclonal antibody. It binds to RHD, the Rhesus factor antigen.[1][2]

It is currently at Phase III trials for Rh disease.

References

[edit]
  1. ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.
  2. ^ Kaplon H, Reichert JM (2018). "Antibodies to watch in 2018". mAbs. 10 (2): 183–203. doi:10.1080/19420862.2018.1415671. PMC 5825203. PMID 29300693.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Roledumab&oldid=1154587963"